Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days (May 27, 28, and 29, 2025) [1] - The company operates under a CDMO business model, providing advanced intermediates of chlorantraniliprole to a long-term partner, with no notification of increased demand from this customer [1] - The company has not identified any significant undisclosed information in public media that could have impacted its stock price [1] Group 2 - The board confirmed that there are no undisclosed matters that should be reported according to the Shenzhen Stock Exchange listing rules, nor any related negotiations or agreements [2] - The company has not found any need to correct or supplement previously disclosed information [2]

证券代码：002250 证券简称：联化科技 公告编号：2025-030 联化科技股份有限公司 关于股票交易异常波动的公告 6、公司不存在违反公平信息披露规定的情形。 三、是否存在应披露而未披露信息的说明 二、公司关注并核实相关情况 针对公司股票交易异常波动，公司对有关事项进行了核查，并问询了公司控 股股东、实际控制人，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司关注到近期公共传媒报道了公司涉及生产氯虫苯甲酰胺的相关内容。 公司目前以CDMO业务模式为客户提供氯虫苯甲酰胺的高级中间体，公司与该客 户是长期合作伙伴关系，产品仅向该客户出售，产品定价模式为成本加成，截至 目前公司尚未收到该客户关于相关产品需求增加的通知。因此，相关事项对公司 整体影响有限。除前述事项外，公司未发现近期公共传媒报道可能或已经对公司 股票交易价格产生较大影响的未公开重大信息。 3、近期公司生产经营情况正常，公司经营情况及内外部经营环境未发生重 大变化。 4、公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大 事项，或处于筹划阶段的重大事项。 5、在公司股票异常波动期间，公司控股股东、实际 ...

Core Viewpoint - The company, Lianhua Technology (002250), has announced that its stock trading has experienced unusual fluctuations, but the overall impact on the company is limited due to the nature of its business model and current operational status [1] Group 1: Business Model and Operations - The company operates under a CDMO (Contract Development and Manufacturing Organization) business model, providing advanced intermediates of chlorantraniliprole exclusively to a single client [1] - The pricing model for the products is based on a cost-plus approach, ensuring stable revenue from the client [1] - As of now, the company has not received any notification from the client regarding an increase in demand for the related products, indicating stable demand [1] Group 2: Market and External Factors - The company has not identified any significant undisclosed information that may have impacted its stock trading price, despite recent media reports [1] - The company's production and operational conditions remain normal, with no significant changes in the internal or external business environment [1]

Group 1 - The U.S. International Trade Court has suspended the Trump administration's comprehensive tariff policy, which was announced on April 2, 2023, citing that the President does not have the constitutional authority to impose such tariffs on nearly all trading partners [4][5]. - The court's ruling allows the administration a maximum of 10 days to halt the imposition of tariffs, following a lawsuit filed by a coalition of 12 states claiming the tariffs were an unlawful exercise of power [5][6]. Group 2 - EDA (Electronic Design Automation) concept stocks in the A-share market have surged, with companies like Guangliwei and Gai Lun Electronics hitting the 20% limit-up, indicating strong market interest in this sector [6][7]. - The global EDA market is dominated by U.S. companies, with Synopsys, Cadence, and Siemens EDA holding a combined market share of 74%, and these companies also control about 80% of the Chinese EDA market [10]. - The Trump administration's recent actions to restrict U.S. companies from selling semiconductor design software to Chinese firms are expected to impact the EDA market dynamics [10]. Group 3 - The pharmaceutical sector has seen a significant rally, with stocks like Shuyou Shen and WuXi AppTec experiencing substantial gains, driven by positive clinical trial results and upcoming major conferences [11][12]. - Shuyou Shen's STSA-1002 injection showed promising results in a clinical trial for ARDS, with mortality rates significantly lower than the control group, which has attracted investor attention [16]. - The ASCO (American Society of Clinical Oncology) annual meeting is set to showcase numerous original research projects from Chinese researchers, highlighting advancements in domestic drug development and increasing competitiveness in the global market [16][17].

A股CRO概念股午后走强，昭衍新药涨停，睿智医药、联化科技此前封板，美迪西涨超10%，凯莱英、 康龙化成、诺思格、药明康德等跟涨。 ...

Market Overview - The A-share market experienced a rebound on May 29, with the ChiNext index leading the gains. The Shanghai Composite Index rose by 0.72%, the Shenzhen Component Index increased by 1.12%, and the ChiNext index gained 1.16%. The total trading volume in the Shanghai and Shenzhen markets reached 743.7 billion yuan, an increase of 91.3 billion yuan compared to the previous trading day. Over 4,400 stocks in the market saw an increase [1]. Sector Performance - Sectors such as unmanned vehicles, digital currency, complete automobiles, and innovative drugs showed significant gains, while sectors like glyphosate, gold, food, and liquor experienced declines [2]. Unmanned Vehicle Sector - The "unmanned driving" concept continued to be active, with several stocks hitting the daily limit. Notable performers included Yunnei Power, Qiming Information, Hexing Shares, and others, with Yunnei Power achieving five consecutive trading limit increases over seven days. The sector is benefiting from supportive policies and capital investments, with the Ministry of Transport planning to expedite the implementation of AI in transportation [5][7]. - The market potential for unmanned delivery vehicles is substantial, estimated at approximately 468 billion yuan, based on the number of logistics points across the country. The delivery volume for leading unmanned delivery vehicle manufacturers is expected to reach tens of thousands by 2025 [7]. Innovative Drug Sector - The CRO (Contract Research Organization) concept also saw strong performance, with stocks like Ruizhi Medicine and Lianhua Technology hitting the daily limit. The innovative drug sector is gaining traction, with several companies set to showcase their research results at the upcoming ASCO annual meeting. The collaboration between domestic companies and global firms is expected to enhance the integration of Chinese innovative drugs into the global supply chain [8].

Group 1 - The pesticide sector shows signs of recovery, with Guangkang Biochemical achieving a 20% limit-up for two consecutive trading days [1] - Other companies such as Lianhua Technology, Xianda Co., Yabenn Chemical, New Agricultural Holdings, and Yingtai Biological also experienced rapid price increases [1] - On May 27, a significant explosion occurred at Shandong Youdao Chemical, the largest global producer of chlorantraniliprole, which accounts for a major share of domestic production capacity [1]

A股CRO概念持续拉升，睿智医药涨停，美迪西涨超8%，成都先导涨近7%，联化科技、凯莱英等跟 涨。 ...

盘后数据出炉。 5月28日，A股市场整体下跌。截至收盘，上证指数报3339.93点，下跌0.02%；深证成指报10003.27点，下跌0.26%； 创业板指报1985.38点，下跌0.31%；北证50指数下跌1.39%。A股市场合计成交10340.73亿元，较上一交易日增加97.78 亿元。 1. A股市场主力资金净流出185.39亿元 今日A股市场主力资金开盘净流出73.21亿元，尾盘净流出22.45亿元，A股市场全天主力资金净流出185.39亿元。 | | | 沪深两市近五日主力资金流向情况（亿元） | | | | --- | --- | --- | --- | --- | | 日期 | | →流入金额 开盘净流入 | | 尾盘净流入 超大单净买入 | | 2025-5-28 | -185. 39 | -73. 21 | -22. 45 | -57. 58 | | 2025-5-27 | -146. 65 | -73.74 | -11. 25 | -28. 63 | | 2025-5-26 | -75. 27 | -51. 21 | 12. 40 | -6. 41 | | 2025-5-23 | -231 ...

Market Overview - On May 28, the Shanghai Composite Index fell by 0.02%, the Shenzhen Component Index decreased by 0.26%, and the ChiNext Index dropped by 0.31% [2] - A total of 43 stocks appeared on the "Dragon and Tiger List" due to unusual trading activity, with the highest net inflow of funds being 175 million yuan into Xue Ren Co., Ltd. (002639.SZ) [2][4] Stock Performance - Xue Ren Co., Ltd. saw a closing price increase of 9.98% with a turnover rate of 51.98%, and it accounted for 4.68% of the total trading volume [4][6] - The stock with the highest net outflow was Guangju Energy (000096.SZ), which experienced a net sell of 110 million yuan, representing 10.6% of its total trading volume, and closed down by 9.97% [4][6] Institutional Activity - On the same day, 21 stocks on the Dragon and Tiger List showed institutional involvement, with institutions net selling a total of 104 million yuan [6][10] - The stock with the highest net purchase by institutions was Qingdao Jinwang (002094.SZ), which closed down by 1.11% with a turnover rate of 43.87% [7][10] Northbound Capital - Northbound funds participated in 9 stocks on the Dragon and Tiger List, with a total net purchase of 205 million yuan [11] - The highest net purchase by northbound funds was also in Xue Ren Co., Ltd., amounting to 45.2 million yuan, which constituted 1.21% of its total trading volume [11][13] Summary of Institutional and Northbound Fund Actions - Institutions and northbound funds jointly net bought stocks such as Yuhua Tian, Huanle Jia, and Guangju Energy, while they jointly net sold stocks like Antong Holdings and Lianhua Technology [13] - There was a divergence in the trading of Shuiyang Co., with institutions net selling 10.5 million yuan while northbound funds net bought 38.3 million yuan [13]